secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcadia Biosciences, Inc. (RKDA)
CIK:        0001469443
Form:       8-K
Filed at:   2022-06-07T23:59:59+00:00
Accession:  0000950170-22-011278
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Arcadia Biosciences CEO Jacot appointed to board; shareholders re-elect directors, ratify auditor, approve executive pay
--------------------------------------------------------------------------------

- CEO Stanley E. Jacot, Jr. appointed as Class III director to fill vacancy from Matthew Plavan's Dec 2021 resignation.
- Annual meeting held June 1, 2022 with 54.40% of outstanding shares present.
- Albert Bolles and Kevin Comcowich elected as Class I directors with 5.5M and 6.1M votes for respectively.
- Deloitte & Touche LLP ratified as auditor for FY2022 with 11.9M votes for, 90k against.
- Say-on-pay advisory vote approved with 5.3M for, 1.3M against, 109k abstain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1469443/000095017022011278/0000950170-22-011278-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1469443/000095017022011278/rkda-20220601.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-011278

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer